Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Universitaet Leipzig

Verified siteinfo

Germany Liebigstrasse 20, Zentrum-Suedost, 04103 Leipzig, Germany

  • 176 trials recruiting
  • Acute myeloid leukaemia · Myelodysplastic syndrome · Plasma cell myeloma
  • Adults and children

About Specializations

Universitaet Leipzig in Leipzig, Germany specialises in clinical trials of conditions such as Acute myeloid leukaemia, Myelodysplastic syndrome, Plasma cell myeloma, Oesophageal adenocarcinoma, and other specialisations. This site conducts important research.

Main research areas of the site

Skin and Connective Tissue Diseases

At Universitaet Leipzig, clinical research in Dermatology, Venereology, and Allergology is centered on skin and connective tissue diseases, with a strong focus on ulcerative pyoderma gangrenosum. The trials are designed to assess whether new treatment approaches can improve outcomes for patients living with this rare and difficult-to-treat inflammatory condition.

  • Studies focused on ulcerative pyoderma gangrenosum and related inflammatory skin disorders
  • Research evaluating the effectiveness and safety of emerging therapies
  • Clinical work aimed at improving treatment options for complex dermatologic disease

With 6 clinical trials and 106 investigators contributing to the program, the site supports focused research on better therapies for this rare skin disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
Liebigstrasse 20, Zentrum-Suedost04103 LeipzigGermany
Open in maps ↗
Recruiting now
176 trials
Conditions studied
290
Partner status
Verified site

More sites in LeipzigGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

423 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Major depression

Recruiting

Study of Brenipatide (LY3537031) in Adults with Major Depressive Disorder to Evaluate Delay of Relapse Compared with Placebo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Ocular myasthenia

Recruiting

A Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Primary progressive multiple sclerosis

Recruiting

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Focal segmental glomerulosclerosis

Recruiting

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim Espana S.A.

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Chronic spontaneous urticaria

Recruiting

A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Loratadine
  • Sponsor:Pfizer Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.